8-K: Harmony Biosciences Eyes $1B WAKIX Revenue in 2026

Harmony Biosciences announced strong preliminary 2025 WAKIX revenue and provided 2026 guidance, alongside updates on its robust late-stage pipeline.

Summary

• Preliminary unaudited net product revenue for the fourth quarter ended December 31, 2025, was approximately $243 million.
• Preliminary unaudited net product revenue for the full year ended December 31, 2025, was approximately $868 million, representing approximately 21% growth year-on-year.
• 2026 WAKIX net revenue guidance is projected between $1.0 billion to $1.04 billion, on track for blockbuster status in narcolepsy.
• The company is advancing its pitolisant franchise with next-generation formulations: pitolisant GR (gastro-resistant) and pitolisant HD (high dose).
• An NDA submission for pitolisant GR is anticipated in 2Q 2026, with an expected PDUFA date in 1Q 2027, and utility patents filed to extend the franchise into the 2040s.
• Pitolisant HD has ongoing Phase 3 registrational clinical trials in narcolepsy (ONSTRIDE 1) and idiopathic hypersomnia (ONSTRIDE 2), with topline data expected in 2027 and an anticipated PDUFA date in 2028.
• The Orexin-2 receptor agonist (BP1.15205) Phase 1 trial is ongoing, with clinical data expected in mid-2026.
• EPX-100 (clemizole hydrochloride) has ongoing Phase 3 registrational trials in Dravet syndrome (ARGUS Study) and Lennox-Gastaut syndrome (LIGHTHOUSE Study), with topline data anticipated in 1H 2027.
• The ZYN002 program in Fragile X syndrome is being phased out, and the 22q deletion syndrome indication is no longer being pursued.

Sentiment

Score: 8

Explanation: The filing presents strong financial performance with significant revenue growth and positive guidance for WAKIX. The robust late-stage pipeline, including next-gen formulations and novel assets, provides multiple future growth catalysts and patent protection into the 2040s. The discontinuation of one program is a minor negative in the context of overall positive developments and a strong financial profile.

Positives

• Achieved preliminary unaudited net product revenue of approximately $868 million for full year 2025, representing approximately 21% growth year-on-year.
• Provided 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion, positioning WAKIX to achieve blockbuster status.
• The average number of patients on WAKIX increased by approximately 400 in Q4 2025, reaching approximately 8,500 patients, marking the third consecutive quarter of significant patient additions.
• Advancing next-generation pitolisant formulations (GR and HD) with utility patents filed to extend the pitolisant franchise into the 2040s.
• Pitolisant GR demonstrated bioequivalence to WAKIX and allowed 100% of patients to initiate treatment at the therapeutic dose without titration in a dosing optimization study.
• Maintains a robust late-stage pipeline with five ongoing Phase 3 registrational clinical trials in five distinct CNS indications.
• The Orexin-2 receptor agonist (BP1.15205) shows potential as a best-in-class candidate based on preclinical potency, selectivity, safety, and potential for once-daily dosing.
• EPX-100 demonstrated a median reduction of approximately 50% in countable motor seizure frequency in participants with at least 6-month exposure in an open-label extension study for Dravet Syndrome.
• The company is profitable and self-funding, supported by a strong balance sheet.
• On track to obtain pediatric exclusivity for WAKIX, which will provide an additional six months of regulatory exclusivity until Q3 2030.

Negatives

• The ZYN002 program in Fragile X syndrome is being phased out.
• Harmony is no longer pursuing a 22q deletion syndrome indication for ZYN002.

Risks

• Commercialization efforts and strategy for WAKIX and, if approved, other product candidates may not be successful.
• The rate and degree of market acceptance and clinical utility of pitolisant in additional indications, if approved, and any other product candidates may be lower than anticipated.
• Research and development plans, including efforts to explore the therapeutic potential of pitolisant in additional indications (pitolisant GR and pitolisant HD), may not yield desired results.
• The ability to expand the scope of license agreements with Bioprojet Socit Civile de Recherche (Bioprojet) may be limited.
• The availability of favorable insurance coverage and reimbursement for WAKIX and, if approved, other product candidates may be uncertain.
• The timing of, and ability to obtain, regulatory approvals for pitolisant for other indications (pitolisant GR and pitolisant HD), as well as any other product candidates, may be delayed or unsuccessful.
• Estimates regarding expenses, future revenue, capital requirements, and additional financing needs may prove inaccurate.
• The ability to identify, acquire, and integrate additional products or product candidates with significant commercial potential that are consistent with commercial objectives may be challenging.
• Significant competition exists in the industry.
• The intellectual property position may not be adequately protected.
• Loss or retirement of key members of management could negatively impact operations.
• Failure to successfully execute the growth strategy, including any delays in planned future growth.
• Failure to maintain effective internal controls.
• The impact of government laws and regulations.
• Volatility and fluctuations in the price of common stock.
• Significant costs and required management time as a result of operating as a public company.
• Actual results, levels of activity, performance, achievements, and events could differ materially from forward-looking statements due to various factors.

Future Outlook

Harmony Biosciences anticipates WAKIX to achieve blockbuster status with over $1 billion in revenue in 2026, driven by continued commercial performance and expansion into new indications. The company is focused on extending the pitolisant franchise into the 2040s through next-generation formulations (GR and HD) and advancing a robust late-stage pipeline, including a potential best-in-class orexin-2 agonist and epilepsy assets, to drive long-term value creation.

Management Comments

• "With WAKIX on track to achieve revenue of over $1 billion in narcolepsy in 2026, Harmony is entering its next phase of growth with significant momentum."
• "Our proven commercial engine is driving exceptional performance with WAKIX, our next-gen formulations are positioned to extend and expand the pitolisant franchise well into the 2040s, and we continue to advance our late-stage pipeline with five ongoing Phase 3 registrational trials toward five distinct CNS indications."
• "As a profitable, self-funding biotech with a strong balance sheet, we are well positioned to build out our pipeline and expand our commercial portfolio to drive long-term value creation."

Industry Context

The announcement highlights Harmony Biosciences' strong position in the rare neurological disease market, particularly for sleep-wake disorders like narcolepsy and idiopathic hypersomnia, and epileptic encephalopathies such as Dravet syndrome and Lennox-Gastaut syndrome. WAKIX, as a first-in-class, non-scheduled treatment, addresses significant unmet needs in narcolepsy where many patients experience residual symptoms and GI disturbances with existing treatments. The development of next-gen pitolisant formulations and a novel orexin-2 agonist positions the company to further differentiate its offerings and potentially capture a larger share of these markets, which are characterized by high unmet medical needs and often debilitating conditions. The discontinuation of the ZYN002 program reflects the inherent risks and competitive landscape in drug development, where programs are regularly evaluated for efficacy and commercial viability.

Comparison to Industry Standards

• WAKIX is highlighted as one of the most successful orphan/rare launches, demonstrating strong commercial performance over six consecutive years.
• WAKIX is the first and only non-scheduled treatment for narcolepsy, differentiating it from other FDA-approved treatments which are scheduled (CII-CIV).
• Pitolisant GR is designed to address GI symptoms experienced by 80-90% of narcolepsy patients, offering a potential improvement over existing formulations and other treatments.
• The orexin-2 receptor agonist (BP1.15205) is positioned as a potential best-in-class candidate based on preclinical data, suggesting superior potency, selectivity, safety, and once-daily dosing compared to other emerging orexin agonists.
• EPX-100's clinically meaningful reduction in seizures for Dravet Syndrome patients, without additional laboratory or special safety monitoring, suggests a favorable risk/benefit profile compared to some existing epilepsy treatments.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, positive future guidance, robust pipeline, and potential for long-term value creation through patent extensions and new product approvals.
• Patients (Narcolepsy, IH, PWS, Dravet, LGS): Potential for new and improved treatment options (pitolisant GR, HD, BP1.15205, EPX-100) addressing unmet needs like GI symptoms, fatigue, sleep inertia, and seizure control.
• Employees: Continued growth and pipeline expansion suggest job stability and potential for further opportunities within the company.
• Customers (Healthcare Providers): Expanded portfolio of differentiated products for various neurological conditions.
• Creditors: Strong financial profile and self-funding status indicate good creditworthiness.

Next Steps

• Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
• NDA submission for pitolisant GR in 2Q 2026.
• Phase 1 clinical PK data for BP1.15205 expected in mid-2026.
• Phase 3 topline data readout for pitolisant in Prader-Willi Syndrome (PWS) in 2H 2026.
• Anticipated PDUFA date for pitolisant GR in 1Q 2027.
• Topline data for EPX-100 Phase 3 trials in Dravet syndrome and Lennox-Gastaut syndrome anticipated in 1H 2027.
• Topline data for pitolisant HD Phase 3 trials (narcolepsy and idiopathic hypersomnia) anticipated in 2027.
• Anticipated PDUFA date for pitolisant HD in 2028.

Key Dates

Recommendation

The company demonstrates exceptional financial health with significant year-over-year revenue growth for WAKIX and robust 2026 guidance projecting blockbuster status. The strategic focus on extending and expanding the pitolisant franchise with next-generation formulations and securing patent protection into the 2040s provides a clear path for sustained long-term revenue. Furthermore, the diverse and innovative late-stage pipeline, including a promising orexin-2 agonist and epilepsy assets, offers multiple catalysts for future growth and diversification. The company's self-funding status and strong balance sheet underscore its operational efficiency and reduced reliance on external financing. While the discontinuation of the ZYN002 program is a minor setback, it is overshadowed by the overall positive developments and strong commercial execution. This combination of current performance, strategic pipeline development, and financial strength makes Harmony Biosciences a compelling investment opportunity.

Keywords

Harmony Biosciences, HRMY, WAKIX, pitolisant, narcolepsy, excessive daytime sleepiness, cataplexy, Prader-Willi Syndrome, PWS, pitolisant GR, pitolisant HD, orexin-2 agonist, BP1.15205, EPX-100, clemizole hydrochloride, Dravet syndrome, DS, Lennox-Gastaut syndrome, LGS, CNS disorders, rare neurological diseases, biotech, pharmaceutical, revenue guidance, clinical trials, pipeline, orphan drug, sleep-wake disorders